NETEC Webinar Series Presentation

Mpox in 2024: Updates and Considerations for Frontline Staff

Release Date: 07/12/2024

Expires: 07/11/2025

CID: 63504

The estimated time to complete this enduring material is 60 minutes.

TARGET AUDIENCE

This accredited continuing education activity is designed for frontline workers, laboratorians, physicians, nurses, and infection preventionists.

EDUCATIONAL OBJECTIVES

At the conclusion of this enduring material, the participant should be better able to:

• Discuss current landscape of Mpox both domestically and internationally.
• Explain the Mpox vaccine recommendations and available treatment options.
• Explain lab considerations for specimen collection and testing.
• Differentiate between categorization of waste.

REQUIREMENTS FOR SUCCESSFUL COMPLETION

In order to receive continuing education credit, you must complete these steps prior to the activity expiration date.

1. View the entire presentation
2. Complete the post-test with a score of 2 out of 3 or better
3. Complete the online evaluation
4. Submit the Completion Attestation

ACCREDITED CONTINUING EDUCATION

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS

The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES/NURSE PRACTITIONERS

The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.

Medical Laboratory Scientists

1 P.A.C.E. credit for medical laboratory scientists.
http://ceorganizer.ascls.org/: Activity Code 346-002-24, Session Code 0725

DISCLOSURE INFORMATION

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

DISCLOSURES

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  

FACULTY

Jonathan Grein, MD
Off-label Disclosure: Tecovirimat for treatment of Mpox

The following faculty have nothing to disclose:

• Vicki Herrera, MS*
• John Horton, MD
• Kari Love, MS, RN, CIC, FAPIC
• Anna Yaffee, MD, MPH*

PLANNING COMMITTEE

The below planning committee members have nothing to disclose:

• Britton Clark, MPH, CNP
• Valeta Creason-Wahl, MMP
• Chimora Imonugo, MD, MPH
• Heidi Keeler, PhD, MSN/MBA, RN
• Benjamin Mattson, MS Ed
• Jason Noble, BA, BFA
• Aileen Patel, MS, RN, CCRN
• Renee Paulin, MSN, RN, CWOCN
• Brenda Ram, CMP, CHCP

FINANCIAL SUPPORT 

This program is funded by ASPR